Ratings by Northland (Tim Chiang)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 3/30/2022 | Kala Pharmaceuticals | KALA | Maintain | Outperform (N/A) |
|
Details | ||
| 3/21/2022 | Oaktree Acquisition Corp II | OACB | New Coverage | Outperform (N/A) |
9.92 (9.38) |
-5.44% | Details | |
| 3/3/2022 | SAB Biotherapeutics | SABS | Maintain | Outperform (N/A) |
|
Details | ||
| 3/1/2022 | Pacira Pharmaceuticals | PCRX | Maintain | Market Perform (N/A) |
|
Details | ||
| 2/15/2022 | BioDelivery Sciences International | BDSI | Downgrade | Market Perform (Outperform) |
5.56 (5.59) |
0.54% | Details | |
| 2/7/2022 | Cyteir Therapeutics | CYT | New Coverage | Outperform (N/A) |
5.91 (3.02) |
-48.9% | Details | |
| 1/3/2022 | Pacira Pharmaceuticals | PCRX | Maintain | Market Perform (N/A) |
|
Details | ||
| 12/2/2021 | SAB Biotherapeutics | SABS | Maintain | Outperform (N/A) |
|
Details | ||
| 11/16/2021 | Kala Pharmaceuticals | KALA | Maintain | Outperform (N/A) |
|
Details | ||
| 10/11/2021 | Protagonist Therapeutics | PTGX | Upgrade | Outperform (Market Perform) |
18.24 (92.09) |
404.88% | Details | |
| 10/4/2021 | Big Cypress Acquisition Corp. | BCYP | New Coverage | Outperform (N/A) |
10.07 (8.44) |
-16.19% | Details | |
| 9/21/2021 | Verrica Pharmaceuticals | VRCA | Maintain | Outperform (N/A) |
|
Details | ||
| 9/17/2021 | Protagonist Therapeutics | PTGX | Downgrade | Market Perform (N/A) |
46.13 (18.24) |
-60.46% | Details | |
| 9/14/2021 | IsoRay, Inc. | ISR | New Coverage | Outperform (N/A) |
0.70 (0.38) |
-45.71% | Details | |
| 8/6/2021 | Kala Pharmaceuticals | KALA | Maintain | Outperform (N/A) |
|
Details | ||
| 7/29/2021 | Protagonist Therapeutics | PTGX | Maintain | Outperform (N/A) |
|
Details | ||
| 6/14/2021 | Protagonist Therapeutics | PTGX | Maintain | Outperform (N/A) |
|
Details | ||
| 5/24/2021 | Protagonist Therapeutics | PTGX | New Coverage | Outperform (N/A) |
34.28 (46.13) |
34.57% | Details | |
| 5/18/2021 | Ironwood Pharmaceuticals | IRWD | Maintain | Outperform (N/A) |
|
Details | ||
| 3/18/2021 | Verrica Pharmaceuticals | VRCA | Maintain | Outperform (N/A) |
|
Details | ||
| 2/18/2021 | Verrica Pharmaceuticals | VRCA | Maintain | Outperform (N/A) |
|
Details | ||
| 2/18/2021 | Ironwood Pharmaceuticals | IRWD | Maintain | Outperform (N/A) |
|
Details | ||
| 2/17/2021 | Verrica Pharmaceuticals | VRCA | Maintain | Market Perform (N/A) |
|
Details | ||
| 2/11/2021 | Pacira Pharmaceuticals | PCRX | Downgrade | Market Perform (Outperform) |
77.29 (22.00) |
-71.54% | Details | |
| 9/21/2020 | Pacira Pharmaceuticals | PCRX | Upgrade | Outperform (Market Perform) |
60.77 (22.00) |
-63.8% | Details | |
| 6/17/2020 | Ironwood Pharmaceuticals | IRWD | New Coverage | Outperform (N/A) |
9.53 (3.50) |
-63.27% | Details | |
| 6/1/2020 | Menlo Therapeutics | MNLO | Maintain | Outperform (N/A) |
|
Details | ||
| 6/1/2020 | Menlo Therapeutics | MNLO | Maintain | Outperform (N/A) |
|
Details | ||
| 5/27/2020 | Pacira Pharmaceuticals | PCRX | Downgrade | Market Perform (Outperform) |
44.54 (22.00) |
-50.61% | Details | |
| 4/22/2020 | BioDelivery Sciences International | BDSI | New Coverage | Outperform (N/A) |
4.06 (5.56) |
36.95% | Details | |
| 4/7/2020 | Pacira Pharmaceuticals | PCRX | New Coverage | Outperform (N/A) |
32.00 (44.54) |
39.19% | Details |
